PureTech Health (LON:PRTC) Trading Up 14.1% - What's Next?

Key Points

• PureTech Health's share price surged by 14.1% during trading, reaching a high of GBX 123 ($1.67) before closing at GBX 121.40 ($1.65), reflecting significant trading activity with a volume increase of 190%.
• The company has a market cap of £293.65 million, a high PE ratio of 714.71, and notable financial ratios including a quick ratio of 2.51 and a current ratio of 3.68.
• Insider Bharatt Chowrira recently purchased 167,739 shares at an average price of GBX 1, which suggests growing confidence from management, with insiders owning 13.13% of the company.

PureTech Health plc (LON:PRTC - Get Free Report) shares traded up 14.1% during mid-day trading on Friday . The company traded as high as GBX 123 ($1.66) and last traded at GBX 121.40 ($1.64). 2,159,675 shares were traded during trading, an increase of 190% from the average session volume of 743,886 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 4.2%

The firm has a market capitalization of £303.07 million, a P/E ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a fifty day moving average of GBX 129.31 and a 200 day moving average of GBX 129.65.

Insider Buying and Selling at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction on Thursday, July 3rd. The stock was acquired at an average price of GBX 1 per share, with a total value of £1,677.39. Company insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.